| Literature DB >> 30388818 |
Isadora T S Bastos1, Pedro de Sena M Pinheiro2,3, Fanny N Costa4, Miguel D Rocha5, Carlos Mauricio R Sant'Anna6,7, Delson Braz8, Everton T Souza9,10, Marco A Martins11,12, Eliezer J Barreiro13,14, Fabio F Ferreira15, Regina C Barroso16, Carlos A M Fraga17,18.
Abstract
Pulmonary arterial hypertension (PAH) is a chronic cardiovascular disease that displays inflammatory components, which contributes to the difficulty of adequate treatment with the available therapeutic arsenal. In this context, the N-acylhydrazone derivative LASSBio-1359 was previously described as a multitarget drug candidate able to revert the events associated with the progression of PAH in animal models. However, in spite of having a dual profile as PDE4 inhibitor and adenosine A2A receptor agonist, LASSBio-1359 does not present balanced potencies in the modulation of these two targets, which difficult its therapeutic use. In this paper, we describe the design concept of LASSBio-1835, a novel structural analogue of LASSBio-1359, planned by exploiting ring bioisosterism. Using X-ray powder diffraction, calorimetric techniques, and molecular modeling, we clearly indicate the presence of a preferred synperiplanar conformation at the amide function, which is fixed by an intramolecular 1,5-N∙∙∙S σ-hole intramolecular interaction. Moreover, the evaluation of LASSBio-1835 (4) as a PDE4 inhibitor and as an A2A agonist confirms it presents a more balanced dual profile, being considered a promising prototype for the treatment of PAH.Entities:
Keywords: N-acylhydrazone; PDE4 inhibitor; X-ray powder diffractometry; adenosine A2A receptor; chalcogen bond; crystal structure determination; sigma-hole
Year: 2018 PMID: 30388818 PMCID: PMC6316713 DOI: 10.3390/ph11040119
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247
Figure 1Design concept of N-acylhydrazone derivatives LASSBio-1834 (3) and LASSBio-1835 (4).
Scheme 1Synthesis of N-acylhydrazone derivatives (3) and (4).
PDE4 inhibitory activity evaluation of LASSBio-1834 (3) and LASSBio-1835 (4).
|
| ||||
|---|---|---|---|---|
| Compounds | PDE4A1A a | PDE4B1 a | PDE4C a | PDE4D3 a |
| R = H ( | 53% | 48% | 12% | 19% |
| R = CH3 ( | 78% | 44% | 22% | 40% |
a Percent inhibition determined at a concentration of 10 µM.
Figure 2Plot from the final Rietveld refinement of LASSBio-1834 (3). Black circles represent observed data; the red line indicates the calculated pattern and the blue line at the bottom represents the difference between the observed and calculated patterns. Magenta vertical bars indicate the Bragg reflections.
Figure 3Plot from the final Rietveld refinement of LASSBio-1835 (4). Black circles represent observed data; the red line indicates the calculated pattern and the blue line at the bottom represents the difference between the observed and calculated patterns. Magenta vertical bars indicate the Bragg reflections.
Figure 4Molecular structure of LASSBio-1834 (3) (a) and LASSBio-1835 (4) (b) compound indicating all atoms as spheres.
Figure 5CAM-B3LYP/6-31G(d) potential energy surfaces of the O=C-N-X dihedral angle for LASSBio-1834 (3) and LASSBio-1835 (4), obtained with the SPARTAN’16 software (Wavefunction, Inc.).
Figure 6CAM-B3LYP/6-31G(d) potential energy surfaces of the O=C-C-S dihedral angle for LASSBio-1834 (3) and LASSBio-1835 (4), obtained with the SPARTAN’16 software (Wavefunction, Inc., Irvine, CA, USA).
Figure 7Natural Bond Orbital (NBO) analysis evaluation of the nN → σ*S-C interaction using the crystallographic coordinates of LASSBio-1834 (3) and LASSBio-1835 (4). The NBO analyses were performed using the CAM-B3LYP/6-311G(d) level of theory using the GAUSSIAN’09 software.
Figure 8Scanning electron microscopy (SEM) image of LASSBio-1834 (3) crystals exhibiting plates shapes and relatively smooth surfaces (a) and LASSBio-1835 (4) crystals exhibiting needle-like shapes (b).